John D Couling
SVP, Entertainment. Files against DLB. Everything below is filed with the SEC within two business days of the trade. Filed as Couling John D.
Every reported line
Purchases, sales, grants, option exercises and shares withheld for tax.
| Company | Action | Value |
|---|---|---|
| DLBDolby Laboratories Inc2026-10-01 | Option exercise10b5-1 plan | $348.8K |
| DLBDolby Laboratories Inc2026-10-01 | Sale10b5-1 plan | $401.1K |
| DLBDolby Laboratories Inc2026-10-01 | Sale10b5-1 plan | $49.6K |
| DLBDolby Laboratories Inc2026-10-01 | Option exercisederivative10b5-1 plan | — |
| DLBDolby Laboratories Inc2026-09-15 | Grant | — |
| DLBDolby Laboratories Inc2026-09-01 | Option exercise10b5-1 plan | $348.8K |
| DLBDolby Laboratories Inc2026-09-01 | Sale10b5-1 plan | $468K |
| DLBDolby Laboratories Inc2026-09-01 | Option exercisederivative10b5-1 plan | — |
| DLBDolby Laboratories Inc2026-08-03 | Option exercise10b5-1 plan | $348.8K |
| DLBDolby Laboratories Inc2026-08-03 | Sale10b5-1 plan | $46.2K |
| DLBDolby Laboratories Inc2026-08-03 | Sale10b5-1 plan | $413.8K |
| DLBDolby Laboratories Inc2026-08-03 | Option exercisederivative10b5-1 plan | — |
| DLBDolby Laboratories Inc2026-07-01 | Option exercise10b5-1 plan | $348.8K |
| DLBDolby Laboratories Inc2026-07-01 | Sale10b5-1 plan | $407.9K |
| DLBDolby Laboratories Inc2026-07-01 | Option exercisederivative10b5-1 plan | — |
Source: SEC Form 4 and Form 144 filings, via EDGAR. Form 144 carries no filer identifier, so those notices are matched to this page by name alone. Value is shares times the reported price, and is blank where the filing priced the transaction at zero — a grant costs its recipient nothing. Insiders sell for reasons that have nothing to do with the company, which is why a sale is not read as a signal on its own.
Follow John D Couling by email
John D Couling's new Form 4 trades, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.